Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Clinical trial NCT04470674 · WITHDRAWN

Trial details

NCT number: NCT04470674
Sponsor: Shirish M Gadgeel
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Cancer Non-small Cell Lung Cancer PD-L1 Gene Mutation KRAS Activating Mutation

Start date: 2021-04-06
Primary completion: 2021-06-08
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.